Updated safety and efficacy results from the phase I study of either LBL-007 (an anti-LAG-3 antibody) in combination with toripalimab (an anti-PD-1 antibody) or LBL-007 in combination with toripalimab and axitinib in patients with advanced melanoma

被引：0
|
作者：
Bai, Xue
Li, Mei
Chen, Yu
Si, Lu
Chen, Jing
Pu, Xingxiang
Cheng, Ying
Zou, Zhengyun
Zhao, Shiwei
Li, Tao
Cai, Shengli
Guo, Jun
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Dept Renal Canc & Melanoma, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[3] Fujian Med Univ, Fujian Canc Hosp, Dept Med Oncol, Clin Oncol Sch, Fuzhou, Peoples R China
[4] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Peoples R China
[5] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Med Sch, Changsha, Peoples R China
[6] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[7] Nanjing Univ, Drum Tower Hosp, Med Sch, Comprehens Canc Ctr, Nanjing, Peoples R China
[8] Nanjing Univ, Clin Canc Inst, Nanjing, Peoples R China
[9] Nanjing Leads Biolabs Co Ltd, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9541
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
    Bendell, Johanna
    Ulahannan, Susanna V.
    Chu, Quincy
    Patel, Manish
    George, Ben
    Landsberg, Renee
    Elgadi, Mabrouk
    Duffy, Christine
    Graeser, Ralph
    Tang, Wenbo
    Merger, Michael
    Ge, Miaomiao
    Johnson, Melissa
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [22] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Coward, Jermaine
    Ben Markman
    Nagrial, Adnan
    Abed, Afaf
    Walpole, Imogen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] A phase I study of Sym021, an anti-PD-1 antibody (Ab), alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
    Spreafico, A.
    Janku, F.
    Rodon, J. A.
    Tolcher, A. W.
    Chandana, S. R.
    Oliva, M.
    Musalli, S.
    Knauss, L.
    Kragh, M.
    Alifrangis, L.
    Frohlich, C.
    Melander, M. C.
    Blondal, T.
    Pedersen, M. W.
    Lantto, J.
    Wood, D.
    Nadler, P. I.
    Horak, I. D.
    Siu, L. L.
    Lakhani, N.
    ANNALS OF ONCOLOGY, 2019, 30 : 488 - +
  • [24] A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies
    Lin, Chia-Chi
    Garralda, Elena
    Schoeffski, Patrick
    Hong, David S.
    Siu, Lillian L.
    Martin, Miguel
    Maur, Michela
    Hui, Rina
    Soo, Ross A.
    Chiu, Joanne
    Zhang, Tian
    Ma, Brigette
    Kyi, Chrisann
    Tan, Daniel S. W.
    Cassier, Philippe A.
    Sarantopoulos, John
    Weickhardt, Andrew
    Carvajal, Richard D.
    Spratlin, Jennifer
    Esaki, Taito
    Rolland, Frederic
    Akerley, Wallace
    Deschler-Baier, Barbara
    Rispoli, Lawrence
    Samant, Tanay S.
    Chowdhury, Niladri Roy
    Gusenleitner, Daniel
    Kwak, Eunice L.
    Askoxylakis, Vasileios
    De Braud, Filippo
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [25] Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)
    Lakhani, N.
    Spreafico, A.
    Tolcher, A. W.
    Rodon, J.
    Janku, F.
    Chandana, S. R.
    Oliva, M.
    Sharma, M.
    Abdul-Karim, R. M.
    Hansen, U. H.
    Hansen, L.
    Skartved, N. J. O.
    Poulsen, T. T.
    Nadal, R. P.
    Lantto, J.
    Wood, D. L.
    Nadler, P. I.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2020, 31 : S704 - S704
  • [26] A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.
    Papadopoulos, Kyriakos P.
    Lakhani, Nehal
    Johnson, Melissa Lynne
    Park, Haeseong
    Wang, Ding
    Yap, Timothy A.
    Moore, Kathleen N.
    Sims, Tasha Nicholle
    Emeremni, Chetachi A.
    Karasarides, Maria
    Kroog, Glenn S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [27] Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
    Coward, Jermaine
    Abed, Afaf
    Nagrial, Adnan
    Markman, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [28] A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb), in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors
    Ganju, Vinod
    Cooper, Adam
    Gao, Bo
    Wilkinson, Kate
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.
    Papadopoulos, Kyriakos P.
    Lakhani, Nehal J.
    Johnson, Melissa Lynne
    Park, Haeseong
    Wang, Ding
    Yap, Timothy Anthony
    Moore, Kathleen N.
    Sims, Tasha Nicholle
    Emeremni, Chetachi
    Karasarides, Maria
    Kroog, Glenn Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Efficacy and safety of LM-108, an anti-CCR8 monoclonal antibody, in combination with an anti-PD-1 antibody in patients with gastric cancer: Results from phase 1/2 studies
    Gong, Jifang
    Liu, Chang
    Yao, Jun
    Xue, Junli
    Dai, Jing
    Ji, Yinghua
    Markman, Ben
    Hiong, Alison
    Yang, Xiuli
    Zhao, Rusen
    Zheng, Yi
    Li, Qingshan
    Wu, Jun
    Barve, Minal A.
    Ariyapperuma, Mihitha Hashara
    Richardson, Gary Edward
    Qin, Xia
    Qin, Crystal Ying
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345